JN Medsys Introduces Clarity digital PCR System

Share Article

JN Medsys unveils its Clarity digital polymerase chain reaction (PCR) system that offers a new paradigm in the absolute quantitation of target nucleic acids requiring high sensitivity and precision. It brings digital PCR analysis to the next level by significantly reducing its preparation time and simplifying its workflow to provide unsurpassed throughput and affordability.

Our aim is to remove all barriers to digital PCR so that more scientists can have access to this powerful technology, and harness it to develop better tests for diseases like cancer or infectious diseases, and to improve the lives of people.

JN Medsys unveils its Clarity digital polymerase chain reaction (PCR) system that offers a new paradigm in the absolute quantitation of target nucleic acids requiring high sensitivity and precision. It brings digital PCR analysis to the next level by significantly reducing its preparation time and simplifying its workflow to provide unsurpassed throughput and affordability.

In making digital PCR faster, easier and more affordable, the Clarity system opens up new opportunities for the detection of mutations in cancer or fetal abnormalities, potentially improving the management and outcomes of these life-threatening diseases. The Clarity digital PCR system was showcased at the American Society for Human Genetics (ASHG) exhibition from 19 to 21 October in San Diego.

Developed with the user in mind, the Clarity digital PCR system features an innovative chip-in-a-tube design that combines the robustness of chip-based partitioning with the ease-of-use of a tube strip. Each PCR mix is rapidly subdivided into 10,000 partitions by a high-density chip. Up to 8 reactions can be run in parallel to yield 80,000 partitions per tube strip.

Capable of running up to 96 reactions per experiment, more samples can now be analyzed in a day to provide unsurpassed digital PCR throughput. Partitioning can be completed within 1 minute and is done in-tube without additional equipment or multiple pipetting steps. It is now possible to do more with less – analyze more samples in less time and with less effort.

“Right from the start, we wanted to develop a product that would transform the way digital PCR was carried out. Our aim is to remove all barriers to digital PCR so that more scientists can have access to this powerful technology, and harness it to develop better tests for diseases like cancer or infectious diseases, and to improve the lives of people. We want our Clarity digital PCR system to be the platform technology that enables that. Our purpose at JN Medsys is to make lives better through providing superior products and outstanding service to our community,” says Johnson Ng, CEO and founder of JN Medsys.

“We are collaborating with JN Medsys to develop more accurate ways to detect and monitor cancer directly from blood using the Clarity digital PCR system. Digital PCR can provide faster and cheaper disease detection, monitoring and clinical care for patients,” says Dr Min-Han Tan, Team Leader and Principal Research Scientist at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR.

JN Medsys launched the early access program for the Clarity digital PCR system at ASHG where up to 5 users would be offered free use of the system. The company is also seeking global distribution partners for the system.

For more information on JN Medsys or the Clarity digital PCR system, please visit http://www.jnmedsys.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Belinda Ling
Visit website